Cargando…

SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays

PURPOSE: For rapid detection and tracking of SARS-CoV-2, alternative method for screening in few hours is highly desirable. Here, we evaluated performance characteristics of TaqMan SARS-CoV-2 mutation panel genotyping molecular assay for detection of most common published SARS-CoV-2 variants using s...

Descripción completa

Detalles Bibliográficos
Autores principales: Neopane, P., Nypaver, J., Shrestha, R., Beqaj, S.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884741/
http://dx.doi.org/10.1016/j.ijid.2021.12.092
_version_ 1784660227444965376
author Neopane, P.
Nypaver, J.
Shrestha, R.
Beqaj, S.S.
author_facet Neopane, P.
Nypaver, J.
Shrestha, R.
Beqaj, S.S.
author_sort Neopane, P.
collection PubMed
description PURPOSE: For rapid detection and tracking of SARS-CoV-2, alternative method for screening in few hours is highly desirable. Here, we evaluated performance characteristics of TaqMan SARS-CoV-2 mutation panel genotyping molecular assay for detection of most common published SARS-CoV-2 variants using specific RT-PCR assays targeting single nucleotide polymorphisms (SNP). METHODS & MATERIALS: A total of 150 SARS-CoV-2 positive samples from March to July were included for this study. In addition, five controls comprised of synthetic RNA B.1.1.7_601443, B.1.351_678597, B.1.351_678597, P.1_792683, B.1.617.1_1662307 and MN908947.3-Wuhan-hu-1 from Twist bioscience and B.1.1.7 (England/204820464/2020) and B.1.351 (South Africa/KRISP-K005325/2020) from (Zeptometrix, NY, USA) were used for validation. RNA from all specimens were extracted using Omega Bio-Tek Mag-Bind Viral RNA Xpress Extraction Kit and tested for known SARS-CoV2 variants using ThermoFisher TaqMan SARS-CoV-2 mutation panel molecular assay on the Quant Studio 12K Flex. Nine representative samples have been compared with sequencing. Data were analyzed by genotype calling using QuantStudio(TM) design and analysis software v2.5 with the genotyping analysis module. RESULTS: All validation controls were tested in triplicate and repeated in singlet on three different days and all reported variants were matching as expected. Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each. 3 (2%) were B.1.526, and 17 (11.3%) have mutation in D614G. Genotyping results from present study showing B.1.617.2, B.1.1.7 and B.1.526 variants and their mutation genes were concordance with sequencing results. CONCLUSION: Our study indicates that TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays detects and differentiate all published common variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), B.1.617.1 (Kappa) and B.1.427/ B.1.429 (Epsilon) that can be used for surveillance and epidemic control and prevention.
format Online
Article
Text
id pubmed-8884741
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88847412022-03-01 SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays Neopane, P. Nypaver, J. Shrestha, R. Beqaj, S.S. Int J Infect Dis Op05.07 (995) PURPOSE: For rapid detection and tracking of SARS-CoV-2, alternative method for screening in few hours is highly desirable. Here, we evaluated performance characteristics of TaqMan SARS-CoV-2 mutation panel genotyping molecular assay for detection of most common published SARS-CoV-2 variants using specific RT-PCR assays targeting single nucleotide polymorphisms (SNP). METHODS & MATERIALS: A total of 150 SARS-CoV-2 positive samples from March to July were included for this study. In addition, five controls comprised of synthetic RNA B.1.1.7_601443, B.1.351_678597, B.1.351_678597, P.1_792683, B.1.617.1_1662307 and MN908947.3-Wuhan-hu-1 from Twist bioscience and B.1.1.7 (England/204820464/2020) and B.1.351 (South Africa/KRISP-K005325/2020) from (Zeptometrix, NY, USA) were used for validation. RNA from all specimens were extracted using Omega Bio-Tek Mag-Bind Viral RNA Xpress Extraction Kit and tested for known SARS-CoV2 variants using ThermoFisher TaqMan SARS-CoV-2 mutation panel molecular assay on the Quant Studio 12K Flex. Nine representative samples have been compared with sequencing. Data were analyzed by genotype calling using QuantStudio(TM) design and analysis software v2.5 with the genotyping analysis module. RESULTS: All validation controls were tested in triplicate and repeated in singlet on three different days and all reported variants were matching as expected. Out of 150 SARS-CoV-2 positive specimens, 69 (46%) were B.1.617.2, 49 (32.7%) were B.1.1.7, P.1 and P.2 were 4 (2.7%) each and B.1.351 and B.1.427/B.1429 were 2 (1.3%) each. 3 (2%) were B.1.526, and 17 (11.3%) have mutation in D614G. Genotyping results from present study showing B.1.617.2, B.1.1.7 and B.1.526 variants and their mutation genes were concordance with sequencing results. CONCLUSION: Our study indicates that TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays detects and differentiate all published common variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), B.1.617.1 (Kappa) and B.1.427/ B.1.429 (Epsilon) that can be used for surveillance and epidemic control and prevention. Published by Elsevier Ltd. 2022-03 2022-02-28 /pmc/articles/PMC8884741/ http://dx.doi.org/10.1016/j.ijid.2021.12.092 Text en Copyright © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Op05.07 (995)
Neopane, P.
Nypaver, J.
Shrestha, R.
Beqaj, S.S.
SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title_full SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title_fullStr SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title_full_unstemmed SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title_short SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular (genotyping) assays
title_sort sars-cov-2 variants detection using taqman sars-cov-2 mutation panel molecular (genotyping) assays
topic Op05.07 (995)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884741/
http://dx.doi.org/10.1016/j.ijid.2021.12.092
work_keys_str_mv AT neopanep sarscov2variantsdetectionusingtaqmansarscov2mutationpanelmoleculargenotypingassays
AT nypaverj sarscov2variantsdetectionusingtaqmansarscov2mutationpanelmoleculargenotypingassays
AT shresthar sarscov2variantsdetectionusingtaqmansarscov2mutationpanelmoleculargenotypingassays
AT beqajss sarscov2variantsdetectionusingtaqmansarscov2mutationpanelmoleculargenotypingassays